Altimmune, Inc. · NASDAQ:ALT
Altimmune — Pharmathene — Merger or Acquisition (August 2013)
21 slides from Altimmune's merger presentation, Aug 1, 2013
Slide 1: Creating a Diversified Biologics Company Addressing Government and Commercial Markets
Creating a Diversified Biologics Company Addressing Government and Commercial Markets
Slide 2: Safe Harbor Statement
2 Safe Harbor Statement Except for the historical information presented herein, matters discussed may constitute forward - looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that are subject to certain risks and uncertainties that could cause actual results
Slide 3: Additional Important Information About the Merger
3 Additional Important Information About the Merger This communication is being made in respect of the proposed merger involving Theraclone Sciences, Inc. and PharmAthene, Inc. PharmAthene will file with the SEC a current report on Form 8 - K, which will include the merger agreement and related docu
Slide 4: PharmAthene / Theraclone
4 PharmAthene / Theraclone PharmAthene, Inc., (NYSE MKT: PIP) a leading biodefense company, and Theraclone Sciences, Inc., a monoclonal antibody discovery and development company, are merging to form a commercially - focused biologics company with extensive vaccines and therapeutics expertise
Slide 5: Combined Company – Investment Opportunity
5 Combined Company – Investment Opportunity Compelling transaction with complementary capabilities to realize synergies and accelerate value Premier biologics company with vaccine and antibody expertise and a focus on infectious diseases and oncology Four clinical programs and multiple partnered pre
Slide 6: Biologics Company with Significant Growth Potential
6 Biologics Company with Significant Growth Potential Non - dilutive funding to drive near - term growth Product development milestones and deals to drive long - term growth DEVELOP SIGNIFICANT COMMERCIAL PRODUCTS DEVELOP GOVERNMENT MARKETS LEVERAGE PROPRIETARY I - STAR™ PLATFORM • Flu Antibody (TNC
Slide 7: New Market Opportunity – Antibody Therapeutics
7 New Market Opportunity – Antibody Therapeutics • Fasted growing segment of the biopharmaceutical industry • Top 6 antibody products have sales of $ 5 billion each annually* • 8 of the top 20 selling biotechnology drugs are monoclonal antibodies • 30 approved products on the market * • Clear regula
Slide 8: Diversified Clinical Pipeline Targeting Large Market Opportunities
8 PRODUCT INDICATION PRE - CLINICAL PHASE I PHASE IIa PHASE IIb MARKET OPPORTUNITIES MARKET POTENTIAL SparVax ® Recombinant protective antigen (rPA) anthrax vaccine Anthrax Infection >$1B TCN - 032 Influenza A Therapeutic Several Seasonal & Pandemic Flu >$500MM TCN - 202 Human Cytomegalovirus Solid
Slide 9: I-STAR Validating Partnerships
9 ISTAR Validating Partnerships January 2011 I - STAR™ collaboration to discover antibodies against up to four undisclosed targets in the areas of infectious disease and cancer. Pfizer has Worldwide licensing rights. 2008 IAVI Innovation Fund collaboration to discover and generate HIV - neutralizing
Slide 10: Flu Antibody: TCN-032
10 Flu Antibody: TNC - 032 • IgG mAb that binds to a novel, highly - conserved universal epitope – Influenza A (H1N1; H5N1; H7N9) • Phase 1 completed; favorable safety and pharmacokinetic profile • Phase 2 a viral challenge completed; data to be presented at a scientific meeting • Annually, 200,000
Slide 11: Cytomegalovirus (CMV) Antibody: TCN-202
11 Cytomegalovirus (CMV) Antibody: TCN - 202 • Recognizes broadly conserved epitope on CMV • Neutralizes CMV viral infection in many cell types – Epithelia, endothelial, fibroblasts, etc. • ~1,000x more potent than plasma - derived CMV - IGIV (pre - clinical studies) • Phase 1 completed; favorable s
Slide 12: SparVax Next Generation Anthrax Vaccine
12 SparVax ® Next Generation Anthrax Vaccine • Highly purified recombinant p rotective antigen – Modern E. coli - based production • 770 individuals in Phase I and Phase II clinical trials • Pre - and post - exposure protection • Enhanced convenience and cost - effectiveness (PEP regimen) – 3 dose I
Slide 13: Valortim Anthrax Anti-Toxin
13 Valortim ® Anthrax Anti - Toxin • Dept. of Homeland Security Material Threat Assessment: 200,000 treatments • HHS procurement program to fulfill requirement Fully human monoclonal antibody (mAb) • Unique mechanism of action similar to natural immune response • Effective Pre - and Post - exposure
Slide 14: Nerve Agent Bioscavenger rBChE
14 Nerve Agent Bioscavenger rBChE Nerve Agent Bioscavenger to Address Chemical Threats • Prevents physiological damage from chemical nerve agents • Robust advanced expression system (AES) technology platform • $5.7MM in DoD funding • Cell culture - based manufacturing • Scalable manufacturing proces
Slide 15: I-STAR Generating Highly-Specific Human Antibodies
15 I - STAR ™ Generating Highly - Specific Human Antibodies for Significant Unmet Medical Needs Selected donor population convalescent/vaccinated subjects = protective Abs Superior B - cell activation Deep sequencing of all hit wells Rapid screen for binding and function IgG+ Memory B - cells “Archi
Slide 16: Significant Near-Term Revenue Opportunity: Arestvyr
16 Significant Near - Term Revenue Opportunity Arestvyr ™ (SIGA Technologies) Oral Smallpox Antiviral Up to ~$2.8B * NOTE: The above based solely on information from the following public sources: SIGA press releases and other public statements, Research analyst reports, SEC filings • $2.8B* U.S. mar
Slide 17: Significant Revenue Opportunity: Arestvyr
17 Significant Revenue Opportunity Arestvyr™ (SIGA Technologies) Oral Smallpox Antiviral • Breach of contract lawsuit filed by PharmAthene in December 2006 • PharmAthene awarded 50% of net profits on WW sales of Arestvyr™ for 10 years by Delaware Court of Chancery in September 2011 • Decision appeal
Slide 18: Combined Company Executive Team
18 Combined Company Executive Team Clifford J. Stocks Chief Executive Officer Calistoga Pharmaceuticals, Inc., ICOS Corporation Russ Hawkinson Chief Financial Officer Corixa Corporation Ernst & Young Kristine Swiderek, Ph.D. Chief Scientific Officer Zymogenetics, National Cancer Center Eleanor L. Ra
Slide 19: Combined Company Board of Directors
19 Combined Company Board of Directors Mitch Sayare, Ph.D. Chairman ImmunoGen XenoGen Clifford J. Stocks Chief Executive Officer Calistoga Pharmaceuticals, Inc., ICOS Corporation Steve Gillis, Ph.D. Immunex, Corixa, ARCH portfolio Eric I. Richman PharmAthene MedImmune, HCV Partners Wende Hutton Cana
Slide 20: Near-Term Valuation Catalysts
20 Near - Term Valuation Catalysts Initiate CMV antibody Phase 2 a study Q3 13 Present Flu Antibody Phase 2a results Q3 13 Present CMV Antibody Phase 1 results Q3 13 Secure additional USG SparVax ® funding Q4 13 Initiate SparVax ® Phase 2 clinical trial Q4 13 Event* Date *The Milestones listed above
Slide 21: Key Terms of the Transaction
21 Key Terms of the Transaction Proposed Transaction: Tax - free, all stock transaction Pro Forma Ownership: Merger of Equals Next Steps: Joint Proxy Statement Prospectus filing Shareholder meeting and vote Name: PharmAthene Public Market: NYSE MKT; symbol “PIP”